Bacteriophage therapy: History and future prospects

Future Virology

Volumn 10, Issue 4, 2015, Pages 449-461

  Clark, Jason R ^a  

^a Novolytics Ltd   (United Kingdom)

Author keywords

antibiotics; bacteriophage; phage; resistance; therapeutic; therapy

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERIOPHAGE; BACTERIOPHAGE THERAPY; BIOFILM; BURN; DIARRHEA; DRUG INDUSTRY; DRUG SAFETY; HUMAN; IMMUNOGENICITY; LIFE CYCLE; NONHUMAN; PERSISTENT INFECTION; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; PROGENY; REVIEW; WAR; WOUND CARE;

ANIMALIA;

EID: 84929085229     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.15.3     Document Type: Review

References (120)

1. Twort FW. An investigation on the nature of ultra-microscopic viruses. Bacteriophage 1(3), 127-129 (2011).
2. Kuhl SJ, Mazure H. Preparation of therapeutic bacteriophages, appendix 1. Translation from: d'Helle F. Le phome de la guison dans les maladies infectieuses masson et cie. OCLC, Paris, France (1938). Bacteriophage 1(2), 55-65 (2011).
3. Sulakvelidze A, Kutter E. Bacteriophage therapy in humans. In: Bacteriophages: Biology and Applications. Kutter E, Sulakvelidze A (Eds). CRC Press, FL, USA, 381-436 (2005).
4. Gski A, Miedzybrodzki R, Borysowski J et al. Bacteriophage therapy for the treatment of infections. Curr. Opin. Investig. Drugs 10, 766-774 (2009).
5. Chanishvili N, Sharp R. A Literature Review of the Practical Application of Bacteriophage Research. Eliava Institute, Tbilisi, GA, USA (2009).
6. Kutter E, De Vos D, Gvasalia G et al. Phage therapy in clinical practice: treatment of human infections. Curr. Pharm. Biotechnol. 11, 69-86 (2010).
7. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections. Bacteriophage 1(2), 66-85 (2011).
8. Hyman P, Abedon ST. Bacteriophages in Health and Disease (Part III). CABI Press, Wallingford, UK (2012).
9. Loc-Carrillo C, Abedon ST. Pros and cons of phage therapy. Bacteriophage 1, 111-114 (2011).
10. Skurnik M, Strauch E. Phage therapy: facts and fiction. Int. J. Med. Microbiol. 296, 5-14 (2006).
11. Abedon ST, Thomas-Abedon C. Phage therapy pharmacology. Curr. Pharm. Biotechnol. 11, 28-47 (2010).
12. Abedon ST. Phage therapy: eco-physiological pharmacology. Scientifica 2014, 1-29 (2014).
13. Payne RJ, Phil D, Jansen VA. Phage therapy: the peculiar kinetics of self-replicating pharmaceuticals. Clin. Pharmacol. Ther. 68(3), 225-230 (2000).
14. Hyman P, Abedon ST. Bacteriophage host range and bacterial resistance. Adv. Appl. Microbiol. 70, 217-248 (2010).
15. Skurnik M, Pajunen M, Kiljunen S. Biotechnological challenges of phage therapy. Biotechnol. Lett. 29, 995-1003 (2007).
16. Rea MC, Alemayehu D, Ross RP, Hill C. Gut solutions to a gut problem: bacteriocins, probiotics and bacteriophage for control of Clostridium difficile infection. J. Med. Microbiol. 62, 1369-1378 (2013).
17. Pez-Cobas AE, Gosalbes MJ, Friedrichs A et al. Gut microbiota disturbance during antibiotic therapy: a multi-omic approach. Gut 62(11), 1591-1601 (2013).
18. Kelly D, McAuliffe O, Ross RP, O'Mahony J, Coffey A. Development of a broad-host-range phage cocktail for biocontrol. Bioeng. Bugs 2(1), 31-37 (2011).
19. Brsow H. Phage therapy: the Western perspective. In: Bacteriophage: Genetics and Microbiology. McGrath S, van Sinderen D (Eds). Caister Academic Press, Norfolk, UK, 159-192 (2007).
20. Midzybrodzki R, Borysowski J, Weber-Dbrowska B et al. Clinical aspects of phage therapy. Adv. Virus Res. 83, 73-121 (2012).
21. Slopek S, Durlakova I, Weber-Dabrowska B, Kucharewicz-Krukowska A, Dabrowski M, Bisikiewicz R. Results of bacteriophage treatment of suppurative bacterial infections. I. General evaluation of the results. Arch. Immunol. Ther. Exp. (Warsz) 31, 267-291 (1983).
22. Merril CR, Scholl D, Adhya SL. The prospect for bacteriophage therapy in Western medicine. Nat. Rev. Drug Discov. 2, 489-497 (2003).
23. Keller R, Engley FB. Fate of bacteriophage particles induced into mice by various routes. Proc. Soc. Exp. Biol. Med. 98, 577-580 (1958).
24. Clark L, Greenbaum C, Jiang J, Lernmark A, Ochs H. The antibody response to bacteriophage is linked to the lymphopenia gene in congenic biobreeding rats. FEMS Immunol. Med. Microbiol. 32, 205-209 (2002).
25. Clark JR, March JB. Bacteriophages and biotechnology: vaccines, gene therapy and antibacterials. Trends Biotechnol. 24(5) 212-218 (2006).
26. Kutter E. Phage therapy: bacteriophages as naturally occurring antimicrobials. In: Practical Handbook of Microbiology. Goldman E, Green LH (Eds). CRC Press, FL, USA, 713-730 (2008).
27. MacNeal WJ, Frisbee FC. One hundred patients with Staphylococcus septicemia receiving bacteriophage service. Am. J. Med. Sci. 191, 179-195 (1936).
28. Meladze GD, Mebuke MG, Chkhetia NS et al. The efficacy of staphylococcal bacteriophage in treatment of purulent diseases of lungs and pleura. Grudn. Khir. 1, 53-56 (1982).
29. Carmody LA, Gill JJ, Summer EJ, et al. Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection. J. Infect. Dis. 201, 264-271 (2010).
30. Ryan EM, Gorman SP, Donnelly RF, Gilmore BF. Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy. J. Pharm. Pharmacol. 63, 1253-1264 (2011).
31. Gski A, Wazna E, Dabrowska BW, Switala-Jel K, Miedzybrodzki R. Bacteriophage translocation. FEMS Immunol. Med. Microbiol. 46, 313-319 (2006).
32. Sarker SA, McCallin S, Barretto C. Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. Virology 434, 222-232 (2012).
33. usiak-Szelachowska M, Zaczek M, Weber-Dbrowska B et al. Phage neutralization by sera of patients receiving phage therapy. Viral Immunol. 27, 295-304 (2014).
34. Hendrix RW. Bacteriophage genomics. Curr. Opinion Microbiol. 6, 506-511 (2003).
35. Clokie MRJ, Kropinski AM. Bacteriophages. Methods and Protocols. Isolation, Characterization and Interactions. Humana Press, NY, USA (2009).
36. Buckling A, Brockhurst M. Bacteria-virus coevolution. Adv. Exp. Med. Biol. 751, 347-370 (2012).
37. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 358, 135-138 (2001).
38. Lewis K. Multidrug tolerance of biofilms and persister cells. Curr. Top. Microbiol. Immunol. 322, 107-131 (2008).
39. Kester JC, Fortune SM. Persisters and beyond: mechanisms of phenotypic drug resistance and drug tolerance in bacteria. Crit. Rev. Biochem. Mol. Biol. 49, 91-101 (2014).
40. Abedon ST. Bacteriophages and Biofilms: Ecology, Phage Therapy, Plaques. Nova Science Publishers, NY, USA (2011).
41. d'Helle F, Smith GH. The Bacteriophage and Its Behaviour. Williams & Wilkins Co., Baltimore, MD, USA (1926).
42. d'Helle F, Malone RH, Lahiri MN. Studies on Asiatic Cholera. Thacker, Spink & Co., Calcutta, India (1930).
43. Beckerich A, Hauduroy P. The Bacteriophage therapy of bacillary dysentery in children. Therapeutic application of bacteriolysants; d'Herelle's phenomenon. Compt. Rend. Soc. Biol. 86, 168 (1922).
44. Davison WC. Das le bacteriophage dans le traitment de la fievre typhoid. Am. J. Dis. Child. 23, 531 (1922).
45. Sharp R. Bacteriophages: biology and history. J. Chem. Technol. Biotechnol. 76, 667-672 (2001).
46. Morison J. Bacteriophage in the Treatment and Prevention of Cholera. HK Lewis and Co, London, UK (1932).
47. Summers WC. Felix d'Herelle and the Origins of Molecular Biology. Yale University Press, CT, USA (1999).
48. Straub ME, Applebaum M. Studies on commercial bacteriophage products. JAMA 100, 110-113 (1933).
49. Hsler T. Viruses vs. Superbugs: A Solution to the Antibiotic Crisis Macmillan, Basingstoke, UK (2006).
50. Kutter EM. Bacteriophage therapy: past and present. In: Encyclopedia of Microbiology. Schaecter M (Ed.). Elsevier, Oxford, UK, 258-266 (2009).
51. Summers WC. In the beginning. Bacteriophage 1(1), 50-51 (2011).
52. Summers WC. The strange history of phage therapy. Bacteriophage 2(2), 130-133 (2012).
53. Wittebole X, De Roock S, Opal SM. A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence 4, 1-10 (2014).
54. Eaton MD, Bayne-Jones S. Bacteriophage therapy: review of the principles and results of the use of bacteriophage in the treatment of infections. JAMA 103, 1769-1939 (1934).
55. Krueger AP, Scribner EJ. The bacteriophage. JAMA 116, 2160-2277 (1941).
56. Morton HE, Engley FB Jr. Dysentery bacteriophage. JAMA 127, 584-591 (1945).
57. Barrow PA, Soothill JS. Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential. Trends Microbiol. 5, 268-271 (1997).
58. Roucourt B, Lavigne R. The role of interactions between phage and bacterial proteins within the infected cell: a diverse and puzzling interactome. Environ. Microbiol. 11, 2789-2805 (2009).
59. Barksdale L, Arden SB. Persisting bacteriophage infections, lysogeny, and phage conversions. Annu. Rev. Microbiol. 28(0), 265-299 (1974).
60. Kuhl S, Abedon ST, Hyman P. Diseases caused by phages. In: Bacteriophages in Health and Disease. Hyman P, Abedon ST (Eds). CABI Press, Wallingford, UK, 256-272 (2012).
61. Fortier L, Sekulovic O. Importance of prophages to evolution and virulence of bacterial pathogens. Virulence 4(5), 354-365 (2013).
62. Lloyd NC, Morgan HW, Nicholson BK, Ronimus RS. The composition of Ehrlich's salvarsan: resolution of a century-old debate. Angew. Chem. Int. Ed. Engl. 44, 941-944 (2005).
63. Bentley R. Different roads to discovery; Prontosil (hence sulfa drugs) and penicillin (hence-lactams). J. Ind. Microbiol. Biotechnol. 36, 775-786 (2009).
64. Grossman CM. The first use of penicillin in the United States. Annal. Intern. Med. 149(2), 135-136 (2008).
65. Parascandola J. The history of antibiotics: a symposium. American Institute of the History of Pharmacy No. 5 (1980).
66. Summers WC. Bacteriophage therapy. Annu. Rev. Microbiol. 55, 437-451 (2001).
67. De Vos D, Verbeken G, Ceulemans C, Huys I, Pirnay, J-P. Reintroducing phage therapy in modern medicine: the regulatory and intellectual property hurdles. In: Phage Therapy: Current Research and Applications. Borysowski J, Midzybrodzki R, Gski A (Eds). Caister Academic Press, Norfolk, UK, 297 (2014).
68. Smith HW, Huggins MB. Successful treatment of experimental Escherichia coli infections in mice using phage: Its general superiority over antibiotics. J. Gen. Microbiol. 128, 307-318 (1982).
69. Smith HW, Huggins MB. Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs. J. Gen. Microbiol. 129, 2659-2675 (1983).
70. Smith HW, Huggins MB, Shaw KM. The control of experimental Escherichia coli diarrhoea in calves by means of bacteriophages. J. Gen. Microbiol. 133, 1111-1126 (1987).
71. Smith HW, Huggins MB, Shaw KM. Factors influencing the survival and multiplication of bacteriophages in calves and in their environment. J. Gen. Microbiol. 133, 1127-1135 (1987).
72. Declaration of Helsinki (2013). www.wma.net
73. Letarov AV, Golomidova AK, Tarasyan KK. Ecological basis of rational phage therapy. Acta Naturae 2, 60-71 (2010).
74. Holland J. Fixing a broken drug development process. J. Comm. Biotech. 19(1), 5-6 (2013).
75. Verbeken G, Pirnay J-P, De Vos, D et al. Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine. Arch. Immunol. Ther. Exp. 6, 161-172 (2012).
76. Intralytix. www.intralytix.com
77. Agency Response Letter GRAS Notice No. GRN 000435. www.fda.gov
78. Sulakvelidze A. The challenges of bacteriophage therapy. European Industrial Pharmacy 10, 14-18 (2011)
79. Omnilytics. www.omnilytics.com
80. Micreos. www.micreos.com
81. FDA GRAS approval for the use of Listex on food products. www.fda.gov
82. Coffey B, Rivas L, Duffy G, Coffey A, Ross RP, McAuliffe O. Assessment of Escherichia coli O157:H7-specific bacteriophages e11/2 and e4/1c in model broth and hide environments. Int. J. Food Microbiol. 147, 188-194 (2011)
83. Goodridge LD, Bisha B. Phage-based biocontrol strategies to reduce foodborne pathogens in foods. Bacteriophage 1(3), 130-137 (2011).
84. Sillankorva, SM, Oliveira H, Azeredo J.Bacteriophages and their role in food safety. Int. J. Microbiol. 2012, 863945 (2012).
85. Endersen L, O'Mahony J, Hill C, Ross RP, McAuliffe O, Coffey A. Phage therapy in the food industry. Annu. Rev. Food Sci. Technol. 5, 327-349 (2014).
86. Jones JB, Vallad GE, Iriarte FB et al. Considerations for using bacteriophages for plant disease control. Bacteriophage 2(4), 208-214 (2012).
87. MacNeal WJ, Frisbee FC, McRae MA. Staphylococcemia 1931-1940: five hundred patients. Am. J. Clin. Path. 12, 281-294 (1942).
88. Rhodes DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS, Sulakvelidze A. Bacteriophage therapy of venous leg ulcers in humans: results of a Phase I safety trial. J. Wound Care 16, 237-243 (2009).
89. A prospective, randomized, double-blind controlled study of WPP-201 for the safety and efficacy of treatment of venous leg ulcers. https://clinicaltrials.gov
90. Merabishvili M, Pirnay JP, Verbeken G et al. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS ONE 4(3), e4944, 1-10 (2009).
91. Rose T, Verbeken G, De Vos D. Experimental phage therapy of burn wound infection: difficult first steps. Int. J. Burn Trauma 4, 66-73 (2014).
92. Harper DR, Burrowes BH, Kutter EM. Bacteriophage: therapeutic uses. In: eLS. John Wiley & Sons Ltd, Chichester, UK (2014).
93. Bruttin A, Brsow H. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob. Agents Chemother. 49, 2874-2878 (2005).
94. Antibacterial treatment against diarrhea in oral rehydration solution. https://clinicaltrials.gov
95. AmpliPhi Biosciences. www.ampliphibio.com
96. Hawkins C, Harper D, Burch D, Anggard E, Soothill J. Topical treatment of Pseudomonas aeruginosa otitis of dogs with a bacteriophage mixture: a before/after clinical trial. Vet. Microbiol. 146, 309-313 (2010).
97. Wright A, Hawkins C, nggd E, Harper D. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngology 34, 349-357 (2009).
98. Slopek S, Weber-Dabrowska B, Dabrowski M, Kucharewicz-Krukowska A. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Arch. Immunol. Ther. Exp. (Warsz) 35, 569-583 (1987).
99. Osawa Y, Miyazaki, K. An empirical analysis of the valley of death: large-scale R&D project performance in a Japanese diversified company. Asian J. Tech. Innov. 14(2), 93-116 (2006).
100. Bush K, Courvalin P, Dantas G et al. Tackling antibiotic resistance. Nat. Rev. Microbiol. 9, 894-896 (2011).
101. World Health Organization. Race against time to develop new antibiotics. Bull. World Health Organ. 89, 88-89 (2011).
102. Projan SJ. Why is big Pharma getting out of antibacterial drug discovery Curr. Opin. Microbiol. 6, 427-430 (2003).
103. Blaser, MJ. Missing Microbes: How the Overuse of Antibiotics is Fuelling our Modern Plagues. Henry Holt and Company, NY, USA (2014).
104. Thuong M, Shortgen F, Zazempa V, Girou E, Soussy CJ, Brun-Buisson C. Appropriate use of restricted antimicrobial agents in hospitals: the importance of empirical therapy and assisted re-evaluation. J. Antimicrobial Chemother. 46, 501-508 (2000).
105. Cooper MA, Shales D. Fix the antibiotics pipeline. Nature 472, 32 (2011).
106. Withington R. Regulatory issues for phage-based clinical products. J. Chem. Technol. Biotechnol. 76, 673-676 (2001).
107. Parracho HM, Burrowes BH, Enright MC, McConville ML, Harper DR. The role of regulated clinical trials in the development of bacteriophage therapeutics. J. Mol. Genet. Med. 6, 279-286 (2012).
108. Verbeken G, De Vos D, Vaneechoutte M, Merabishvili M, Zizi M, Pirnay JP. European regulatory conundrum of phage therapy. Future Microbiol. 2, 485-491 (2007).
109. Marwick C. Merits, flaws of live flu vaccine debated. JAMA 283, 1814-1815 (2000).
110. Verbeken G, Huys I, Pirnay J-P et al. Taking bacteriophage therapy seriously: a moral argument. BioMed. Res. Int. 2014, 621316, 1-8 (2014).
111. Pirnay J-P, De Vos D, Verbeken G et al. The phage therapy paradigm: pr-porter or sur-mesure Pharm. Res. 28(4), 934-937 (2011).
112. Huys I, Pirnay J-P, Lavigne R et al. Paving a regulatory pathway for phage therapy. EMBO reports 14(11), 951-954 (2013).
113. Medicines, medical devices and blood regulation and safety-guidance. Good manufacturing practice and good distribution practice. www.mhra.gov.uk
114. Vandamme EJ. Phage therapy and phage control: to be revisited urgently!! J. Chem. Technol. Biotechnol. 89, 329-333 (2014).
115. Klumpp J, Fouts DE, Sozhamannan S. Next generation sequencing technologies and the changing landscape of phage genomics. Bacteriophage. 2(3), 190-199 (2012).
116. Henein, A. What are the limitations on the wider therapeutic use of phage Bacteriophage 2, e24872 (2013).
117. Merabishvili M, De Vos D, Verbeken G et al. Selection and characterization of a candidate therapeutic bacteriophage that lyses the Escherichia coli O104:H4 strain from the 2011 outbreak in Germany. PLoS ONE 7(12), e52709 (2012).
118. Evaluation of phage therapy for the treatment of Escherichia coli and Pseudomonas aeruginosa wound infections in burned patients (PHAGOBURN). https://clinicaltrials.gov
119. PhagoBurn. www.phagoburn.eu
120. Reardon S. Phage therapy gets revitalized. Nature 510(7503), 15-16 (2014).